Addyi Cost in Idaho 2026: Flibanserin Prices, Insurance, and Compounding Options

What Is Flibanserin (Addyi) and Why Does Cost Vary by State?

Flibanserin is the only FDA-approved non-hormonal medication for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA granted approval on August 18, 2015, after two prior rejection cycles, under a Risk Evaluation and Mitigation Strategy (REMS) program that has since been removed [1]. Because flibanserin has no FDA-approved generic competitor and because state Medicaid programs set their own formularies independently, the out-of-pocket cost a patient pays in Idaho can differ sharply from what a patient in California or New York pays.

HSDD is not a fringe diagnosis. The condition affects an estimated 8 to 10 percent of premenopausal women in the United States, and the DSM-5 criteria require that distress or interpersonal difficulty must accompany the low-desire symptom pattern [2]. Sprout Pharmaceuticals holds the exclusive brand rights to Addyi, which gives the company pricing power in the absence of generic competition.

The BEGONIA trial, published in the Journal of Sexual Medicine in 2014 (N=1,378), demonstrated that flibanserin 100 mg at bedtime produced a statistically significant increase in satisfying sexual events compared to placebo over 24 weeks, with the most common adverse effects being dizziness, somnolence, nausea, and fatigue [3]. Understanding that clinical profile matters for Idaho prescribers weighing whether a patient's insurance situation makes the drug accessible at all.

State-level cost variation is driven by three factors: whether Medicaid covers the drug, whether commercial insurers in that state include it on formulary, and whether licensed 503A compounding pharmacies operate in the state. All three factors affect Idaho patients directly.

Addyi Brand-Name Price in Idaho: What Cash-Pay Patients Actually Pay

The manufacturer list price for brand-name Addyi in Idaho is $880 per month as of 2026. That figure represents 30 tablets of flibanserin 100 mg at the standard once-nightly dosing frequency.

Cash-pay is the default scenario for most Idaho patients because Medicaid excludes Addyi and private-plan coverage is inconsistent. At $880 per month, annual cost reaches $10,560 before any savings program is applied. That price point places Addyi among the more expensive specialty medications for a non-life-threatening condition, which partly explains why adherence data from post-approval studies have been modest.

The FDA label for Addyi (NDA 022526) documents the approved dosing as 100 mg orally at bedtime, with a specific warning to avoid alcohol and CNS depressants due to risk of severe hypotension and syncope [1]. That black-box warning historically contributed to commercial payer reluctance to cover the drug, because managed care pharmacy directors frequently cite safety-related utilization concerns as a formulary exclusion rationale.

GoodRx and similar discount aggregators do list flibanserin at some Idaho retail pharmacies, and prices through those channels have ranged from roughly $820 to $880 per month depending on the specific pharmacy location in Boise, Idaho Falls, or Pocatello. These prices fluctuate and should be verified directly with the dispensing pharmacy at the time of prescription pickup.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction notes that shared decision-making between clinician and patient should account for cost burden, particularly for medications where efficacy signals are modest in absolute terms [4]. For Idaho patients without coverage, that conversation is often the deciding factor in whether a prescription ever gets filled.

Idaho Medicaid Coverage for Addyi: The Current Status

Idaho Medicaid does not cover Addyi as of 2026. The Idaho Medicaid Preferred Drug List maintained by the Department of Health and Welfare does not include flibanserin on any covered tier, meaning prior authorization pathways that exist for some excluded drugs are also unavailable through the standard Medicaid process.

This coverage gap affects a meaningful patient population. Idaho Medicaid enrollment covered approximately 380,000 individuals in fiscal year 2024, and premenopausal women represent a substantial share of that group. Without coverage, Medicaid enrollees face the full $880 monthly list price unless they access compounded flibanserin through a 503A pharmacy.

The exclusion is not unique to Idaho. Across the United States, fewer than half of state Medicaid programs include flibanserin on their formularies, largely because the Centers for Medicare and Medicaid Services (CMS) does not mandate coverage for drugs treating conditions classified as sexual dysfunction in the same way it mandates coverage for cardiovascular or diabetes medications [5]. CMS guidance on Medicaid drug coverage determinations is publicly available through the agency's Medicaid Drug Rebate Program documentation [5].

Patients who believe they may qualify for an exception should ask their prescribing clinician to submit a medical necessity letter directly to Idaho Medicaid, even though approval rates for that pathway are low for Addyi specifically. A documented trial of behavioral therapy or couples counseling, combined with a severity score from a validated instrument such as the Female Sexual Function Index (FSFI), strengthens any appeal.

Compounded Flibanserin in Idaho: 503A Legality and Practical Access

Compounded flibanserin is legally available to Idaho patients through 503A pharmacies licensed in Idaho. This is a meaningful access pathway.

Under federal law, Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs, including drugs that have an FDA-approved commercially available equivalent, when a licensed prescriber writes a patient-specific prescription [6]. The FDA has not placed flibanserin on its list of drugs that may not be compounded, which means 503A pharmacies are free to compound it as a patient-specific preparation [6].

The practical cost difference between brand-name Addyi and compounded flibanserin is substantial. While brand Addyi runs $880 per month, compounded flibanserin from a 503A pharmacy typically costs far less, with some telehealth-affiliated compounding pharmacies pricing 30-day supplies in the range of $60 to $150 depending on formulation, excipients, and dispensing fees. That price difference makes compounding the primary access route for uninsured or underinsured Idaho patients.

Idaho's Board of Pharmacy licenses and regulates 503A compounding pharmacies operating within the state. Patients should confirm that any pharmacy filling a compounded flibanserin prescription holds a current Idaho Board of Pharmacy license and is in good standing. Out-of-state 503A pharmacies that ship to Idaho must hold a non-resident pharmacy permit from Idaho [7].

Quality considerations are real. Compounded preparations are not FDA-tested for potency, sterility, or stability in the same way approved drugs are. The FDA's guidance on 503A compounding quality standards outlines the USP standards that licensed pharmacies must follow [6]. Patients should request a certificate of analysis from any compounding pharmacy before accepting a compounded medication.

The HealthRX clinical team uses a three-step decision framework when helping Idaho patients choose between brand Addyi and compounded flibanserin:

1. Confirm the diagnosis meets DSM-5 HSDD criteria and that non-pharmacologic options have been discussed, per the International Society for the Study of Women's Sexual Health (ISSWSH) process-of-care guidelines [8].
2. Check current commercial insurance formulary status before assuming exclusion, because plan formularies change annually in January.
3. If cost is the limiting factor, route the patient to a licensed Idaho 503A pharmacy with documented USP 795 compliance and request a certificate of analysis on the compounded batch.

Insurance Coverage for Addyi in Idaho: Commercial Plans

Commercial insurance coverage for Addyi in Idaho is inconsistent across carriers and plan types. No major Idaho commercial insurer, including Regence BlueShield of Idaho, Blue Cross of Idaho, SelectHealth, or PacificSource, lists flibanserin as a standard formulary drug on their 2026 individual or small-group plan tiers.

Some large employer self-funded plans in Idaho administer through pharmacy benefit managers (PBMs) such as CVS Caremark, Express Scripts, or OptumRx. These plans have independent formulary decisions, and a small minority do include flibanserin under specialty tier status with prior authorization requirements. Prior authorization criteria typically require documentation of HSDD diagnosis, confirmation of premenopausal status, and absence of contraindicated medications.

Patients covered under employer-sponsored plans should call the member services number on the back of their insurance card and specifically ask whether NDC 68151-0501-30 (Addyi 100 mg, 30-tablet pack) is covered under their pharmacy benefit, and at what tier. This direct NDC query bypasses the generic drug-name search that sometimes misclassifies specialty medications.

If coverage is denied, an appeal citing the clinical trial evidence from BEGONIA [3] and the American College of Obstetricians and Gynecologists (ACOG) guidance on HSDD may support reconsideration [9]. ACOG has stated that flibanserin is an appropriate treatment option for premenopausal women with HSDD who have not responded to psychosocial interventions [9].

Telehealth Prescribing of Addyi in Idaho: How It Works

Telehealth prescribing of flibanserin is fully legal in Idaho, and the state has not imposed restrictions on the type of provider who can prescribe it beyond the standard requirement for a valid prescriber-patient relationship [10].

Idaho allows synchronous video and asynchronous telehealth encounters for prescription of Schedule IV and non-scheduled drugs. Flibanserin is not a controlled substance, so prescribing via telehealth does not require the in-person visit that certain controlled substances mandate under federal law.

Several telehealth platforms operating in Idaho, including HealthRX and others, offer flibanserin prescribing services. The clinical evaluation typically takes 20 to 30 minutes and involves screening for contraindicated medications (including CYP2C19 inhibitors such as fluconazole, which can increase flibanserin plasma concentrations by up to 7-fold according to the FDA label) [1] and discussing realistic efficacy expectations.

Efficacy data deserve honest framing. A Cochrane systematic review of flibanserin trials found that active-treatment patients reported approximately 0.5 additional satisfying sexual events per month compared to placebo, alongside higher rates of dizziness and somnolence [11]. That effect size is real but modest, and patients benefit from understanding it before starting treatment.

After a telehealth prescription is written, the prescription may be sent to any Idaho-licensed pharmacy, including compounding pharmacies. The prescribing clinician should document the HSDD diagnosis using ICD-10 code F52.0 and note counseling on the alcohol interaction in the visit record.

The Sprout Pharmaceuticals Savings Card in Idaho

Sprout Pharmaceuticals offers a patient savings card for commercially insured patients that can reduce the out-of-pocket cost of brand Addyi. As of 2026, the program is accessible through the official Addyi website, and eligible commercially insured patients may pay as little as $25 to $99 per month depending on current program terms.

The savings card is not available to patients enrolled in federal or state government health programs, including Idaho Medicaid, Medicare, or CHIP. This exclusion is standard for manufacturer copay assistance cards and reflects federal anti-kickback statute compliance.

For uninsured patients, Sprout has at different times offered a separate patient assistance program. Eligibility criteria, income thresholds, and program availability change periodically, so patients should contact Sprout Pharmaceuticals directly at the phone number listed on the FDA-approved Addyi patient information sheet [1] to confirm current program status before their prescription is written.

Pharmacies that participate in the savings card program include major retail chains operating in Idaho such as Walgreens, CVS, Rite Aid, and some independent pharmacies. The prescribing telehealth clinician or brick-and-mortar provider should verify pharmacy participation at the time of prescribing to avoid a billing mismatch at pickup.

Comparing Total Annual Cost: Brand vs. Compounded Flibanserin in Idaho

The annual cost difference between brand-name Addyi and compounded flibanserin in Idaho can exceed $8,000 per year for a cash-pay patient.

Brand Addyi at list price: $880 per month, $10,560 per year.

Brand Addyi with the Sprout savings card (commercially insured, best-case scenario): approximately $300 to $1,200 per year depending on copay tier and card terms.

Compounded flibanserin through a licensed Idaho 503A pharmacy: estimated $60 to $150 per month, or $720 to $1,800 per year.

For patients who respond well to flibanserin and plan to use it long-term, the compounding route represents a meaningful reduction in financial burden. The trade-off is the absence of FDA batch-testing for the compounded product. Some clinicians recommend starting with a one-month supply of the compounded preparation to confirm tolerability before committing to ongoing use.

The International Society for the Study of Women's Sexual Health published a position statement noting that flibanserin produces modest but statistically significant improvements in desire and satisfying sexual events compared to placebo, and that clinicians should weigh individual patient values and preferences, including cost, in the treatment decision [8].

What Idaho Clinicians Should Document When Prescribing Flibanserin

Prescribers in Idaho, whether seeing patients in-person or via telehealth, should document five elements to support coverage appeals, prior authorization requests, and medico-legal records:

First, the DSM-5 diagnosis of female sexual interest and arousal disorder (FSIAD) or HSDD, confirmed by validated screening such as the Decreased Sexual Desire Screener (DSDS) [12]. Second, confirmation that the patient is premenopausal, because flibanserin is not FDA-approved for postmenopausal women. Third, a medication reconciliation confirming absence of moderate or strong CYP3A4 inhibitors such as ketoconazole and fluconazole, which carry a contraindication on the Addyi label [1]. Fourth, counseling on the alcohol and CNS depressant interaction and documentation that the patient understands the risk [1]. Fifth, a note on whether psychosocial or behavioral therapy was offered, consistent with ISSWSH process-of-care standards [8].

This documentation supports prior authorization approval rates and protects the prescriber in the event of an adverse outcome claim.

Monitoring and Follow-Up for Idaho Flibanserin Patients

After initiating flibanserin, standard clinical practice is to assess response at eight weeks using a validated tool such as the FSFI or the Female Sexual Distress Scale-Revised (FSDS-R) [13]. The drug should be discontinued in patients who report no improvement in satisfying sexual events or desire after eight weeks, because non-responders at eight weeks are unlikely to benefit with continued use, based on trial data from the SNOWDROP and VIOLET studies that informed the FDA approval package [1].

Patients who do respond and wish to continue should have a follow-up every six months to reassess diagnosis, review concomitant medications, and confirm the patient remains premenopausal. Transition to menopause changes the risk-benefit profile because the drug lacks approved efficacy data in postmenopausal women [1].

Blood pressure monitoring at the first follow-up visit is appropriate given the hypotension signal documented in the FDA label, particularly for patients on antihypertensive medications [1].

For Idaho patients accessing flibanserin through a telehealth platform, follow-up can occur via the same synchronous video or asynchronous messaging platform used for the initial encounter, consistent with Idaho's telehealth practice standards [10].